Latest Headlines

Latest Headlines

Early Gilenya generics now spell trouble for rival MS drugs

Last week, the U.S. Patent Trial and Appeal Board took a long-term Gilenya patent out of commission, putting the Novartis multiple sclerosis drug in line for early generic competition.

Novartis targets Amgen's Enbrel with second biosimilar app

Right now, Novartis' Sandoz has the only biosimilar on the U.S. market. And it's looking to make it two.

Novartis comes for Enbrel in latest biosimilar shot at Amgen

A month removed from launching the U.S.'s first biosimilar, Novartis is again setting sights on an Amgen cash cow, lining up for FDA approval with a copy of the blockbuster Enbrel.

Facing a crisis, Xoma buys time with a $517M Novartis deal

Xoma has worked a deal to outlicense a cancer antibody to its longtime partners at Novartis. In the deal Xoma will get $37 million in badly needed cash upfront, some relief on $13.5 million in debt and the chance to earn $480 million in milestones, if all goes as planned.

Novartis stacks up more data for lucrative Cosentyx expansion

Novartis is chasing a pair of new uses for brand-new psoriasis med Cosentyx, and when it comes to psoriatic arthritis, it's piling up the positive data.

UPDATED: Novartis falls short in controversial IPR process as board nixes Gilenya patent

The U.S. Patent and Trademark Office's review board has dealt its first blow to Big Pharma. The appeal panel nixed a patent on Novartis' multiple sclerosis blockbuster Gilenya, handing a win to challenger Torrent Pharmaceuticals--and fellow generics makers Mylan and Apotex, which had filed a separate challenge.

Novartis issues voluntary recall of ADHD drug manufactured in Georgia

Novartis has issued a voluntary recall of more than 10,000 bottles of a drug used to treat attention deficit hyperactivity disorder (ADHD) that were manufactured at a plant in Georgia.

Novartis backs DC Comics graphic novel starring rare-disease hero and his canine sidekick

Batman and Superman can add another superhero to their ranks at publisher DC Comics, and that's Scott. The teenage protagonist and his trusty sidekick--Turbo the toy dog--feature in the company's latest graphic novel, which Novartis partnered to create for teens with tuberous sclerosis complex.

Novartis scores EU rec for blockbuster-to-be Entresto

Novartis has predicted that its launch of newly FDA-approved heart failure med Entresto would be its "most exciting" ever. And now, it's one step closer to bringing that excitement to Europe.

Novartis' top scientist is stepping down after 13 years, making way for a Harvard luminary

Mark Fishman, head of Novartis' $10 billion research operation, is retiring next year, making way for an award-winning Harvard oncologist after 13 years at the helm.